Daunorubicin hydrochloride
![Daunorubicin hydrochloride Structure](CAS/GIF/23541-50-6.gif)
- CAS No.
- 23541-50-6
- Chemical Name:
- Daunorubicin hydrochloride
- Synonyms
- DAUNORUBICIN HCL;Cerubidine;DAUNOMYCIN HCL;DAUNOMYCIN HYDROCHLORIDE;(8S-cis)-8-Acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione hydrochloride;ondena;CS-585;daunoblastin;ndc0082-4155;daunoblastina
- CBNumber:
- CB7113022
- Molecular Formula:
- C27H30ClNO10
- Molecular Weight:
- 563.98
- MOL File:
- 23541-50-6.mol
- MSDS File:
- SDS
- Modify Date:
- 2024/8/22 14:21:17
Melting point | 190°C (dec) |
---|---|
alpha | D20 +248 ±5° (c = 0.05-0.1 in methanol) |
storage temp. | Inert atmosphere,2-8°C |
solubility | Freely soluble in water and in methanol, slightly soluble in alcohol, practically insoluble in acetone. |
form | solid |
color | red to deep red |
Water Solubility | Soluble in water (50 mM) |
λmax | 477nm(H2O)(lit.) |
Sensitive | Hygroscopic |
Merck | 14,2832 |
BRN | 4229221 |
Stability | Stability |
EPA Substance Registry System | Daunorubicin hydrochloride (23541-50-6) |
SAFETY
Risk and Safety Statements
Symbol(GHS) | ![]() ![]() GHS06,GHS08 |
|||||||||
---|---|---|---|---|---|---|---|---|---|---|
Signal word | Danger | |||||||||
Hazard statements | H301-H341-H351-H360FD | |||||||||
Precautionary statements | P201-P202-P264-P270-P280-P301+P310 | |||||||||
Hazard Codes | Xn,Xi | |||||||||
Risk Statements | 22-40-42/43-36/37/38-20/21/22 | |||||||||
Safety Statements | 22-36/37-45-37/39-36-26 | |||||||||
RIDADR | UN 2811 6.1/PG 3 | |||||||||
WGK Germany | 3 | |||||||||
RTECS | HB7878000 | |||||||||
F | 3-10 | |||||||||
HazardClass | 6.1(b) | |||||||||
PackingGroup | III | |||||||||
HS Code | 29419059 | |||||||||
Toxicity | LD50 in mice (mg/kg): 26 i.v. (DiMarco, 1969) | |||||||||
NFPA 704 |
|
Daunorubicin hydrochloride price More Price(6)
Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
---|---|---|---|---|---|---|---|
Sigma-Aldrich(India) | D8809 | Daunorubicin hydrochloride meets USP testing specifications | 23541-50-6 | 1MG | ₹3972.78 | 2022-06-14 | Buy |
Sigma-Aldrich(India) | D8809 | Daunorubicin hydrochloride meets USP testing specifications | 23541-50-6 | 10MG | ₹17449.9 | 2022-06-14 | Buy |
Sigma-Aldrich(India) | 30450 | Daunorubicin hydrochloride ≥90% (HPLC) | 23541-50-6 | 5MG | ₹12621.95 | 2022-06-14 | Buy |
Sigma-Aldrich(India) | 30450 | Daunorubicin hydrochloride ≥90% (HPLC) | 23541-50-6 | 25MG | ₹28718.73 | 2022-06-14 | Buy |
TCI Chemicals (India) | D4532 | Daunorubicin Hydrochloride | 23541-50-6 | 20MG | ₹4700 | 2022-05-26 | Buy |
Daunorubicin hydrochloride Chemical Properties,Uses,Production
Chemical Properties
Dark Red Crystals
Uses
Anthracycline antibiotic related to the rhodomycins. Antineoplastic
General Description
Orange-red powder. Thin red needles decomposing at 188-190°C. An anti-cancer drug.
Air & Water Reactions
Water soluble.
Reactivity Profile
Daunorubicin hydrochloride may emit toxic oxides of nitrogen when heated.
Biological Activity
Anticancer agent that is clinically used to treat nonlymphocytic leukaemia. Inhibits RNA and DNA synthesis and causes DNA fragmentation in vivo .
Pharmacokinetics
Like Doxil (the liposomal formulation of doxorubicin), DaunoXome is indicated for use in AIDS-related Kaposi's sarcoma and is administered IV at a dose of 40 mg/m2 every 2 weeks. The pharmacokinetic profiles of Doxil and DaunoXome are similar.
Clinical Use
Daunorubicin is administered IV at a dose of 45 mg/m2 for the treatment of lymphocytic and nonlymphocytic leukemia.
Metabolism
The 18.5-hour terminal half-life of daunorubicin is approximately half that of doxorubicin, and the terminal half-life of the active daunorubicinol metabolite is 26.7 hours. Excretion is approximately 40% biliary and 25% urinary.
Daunorubicin hydrochloride Preparation Products And Raw materials
Raw materials
1of2
chevron_rightPreparation Products
Supplier | Tel | Country | ProdList | Advantage | Inquiry |
---|---|---|---|---|---|
GLP Pharma Standards | +91 9866074638 | Hyderabad, India | 1644 | 58 | Inquiry |
Hetero Drugs Limited | +91-4023704923 +91-4023704923 | Telangana, India | 296 | 58 | Inquiry |
Sakar Healthcare | +91-8976292690 +91-9967572302 | Gujarat, India | 47 | 58 | Inquiry |
AKASH PHARMA EXPORTS | +91-9388123451 +91-9846039283 | Kerela, India | 470 | 58 | Inquiry |
CLEARSYNTH LABS LTD. | +91-22-45045900 | Hyderabad, India | 6351 | 58 | Inquiry |
TCI Chemicals (India) Pvt. Ltd. | 1800 425 7889 | New Delhi, India | 6778 | 58 | Inquiry |
SynZeal Research Pvt Ltd | +1 226-802-2078 | Gujarat, India | 6522 | 58 | Inquiry |
Pharmaffiliates Analytics and Synthetics P. Ltd | +91-172-5066494 | Haryana, India | 6773 | 58 | Inquiry |
Padarsh Pharmaceuticals Pvt Ltd | 08048250254Ext 694 | Mumbai, India | 9 | 58 | Inquiry |
Euroasia Trans Continental | +91 22 56349035-36 | New Delhi, India | 519 | 47 | Inquiry |
23541-50-6(Daunorubicin hydrochloride)Related Search:
1of4
chevron_right